| Bioactivity | Dual AChE-MAO B-IN-3 (compound C10) is a potent dual AChE/MAO-B inhibitior, with IC50 values of 0.58 and 0.41 μM, respectively. Dual AChE-MAO B-IN-3 is a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. Dual AChE-MAO B-IN-3 can be used for Alzheimer’s disease (AD) research[1]. |
| Invitro | Dual AChE-MAO B-IN-3 (compound C10) (0-100 μM, 24 h) exhibits low neurotoxicity, and (0-10 μM, 24 h) potently inhibits AChE enzymatic activity[1].Dual AChE-MAO B-IN-3 more effectively protects against mitochondrial dysfunction and oxidation than Donepezil (HY-14566), strongly inhibits AChE-induced amyloid aggregation, and moderately reduces glutaraldehyde-induced phosphorylation of tau protein in SH-SY5Y cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Dual AChE-MAO B-IN-3 (compound C10) (10 mg/kg, IP, once daily for 10 consecutive days) displays largely enhanced improvements in cognitive behaviors and spatial memory in a scopolamine-induced AD mice model with better efficacy than Donepezil (HY-14566)[1]. Animal Model: |
| Name | Dual AChE-MAO B-IN-3 |
| Formula | C30H26F3NO3 |
| Molar Mass | 505.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li X, et al. Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease. ACS Chem Neurosci. 2022 Nov 16. |